oNKo-innate
Business Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
27 Norwood Cres, Moonee Ponds, Victoria,...Website
www.onko-innate.comRevenue
$15.5 MillionIndustry
About oNKo-innate
oNKo-innate is an Australian immuno-oncology company that leverages its profound understanding of the immune system to develop next-generation cancer therapies. The company employs a technology-enabled, biology-driven approach and specializes in natural killer cell therapies, expanding its capabilities across various immuno-oncology targets. With integrated platforms in target discovery, computational biology, and therapeutic development, oNKo-innate is dedicated to overcoming obstacles in solid tumor therapy and exploring broader applications in immunology. Their mission is to transform innovative ideas into effective immunotherapies for cancer patients.Explore more
oNKo-innate Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to oNKo-innate
Compare insights from companies similar to oNKo-innate, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
oNKo-innate Tech Stack
A closer look at the technologies used by oNKo-innate
See more technologies
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding oNKo-innate
Sign Up For FreeTo access detailed company insights
oNKo-innate is an Australian immuno-oncology company that leverages its profound understanding of the immune system to develop next-generation cancer therapies. The company employs a technology-enabled, biology-driven approach and specializes in natural killer cell therapies, expanding its capabilities across various immuno-oncology targets. With i... Read More
